- Beyond Air, Inc. (NASDAQ:XAIR) reported an earnings per share (EPS) of -$0.77, missing analyst estimates of -$0.57.
- Despite missing quarterly revenue estimates, Beyond Air achieved $7.7 million in full-year fiscal 2026 revenue, marking a significant 107% year-over-year increase.
- The medical device company demonstrates strong liquidity with a current ratio of 5.12 and projects substantial revenue growth for 2027.
Beyond Air, Inc. (NASDAQ:XAIR) is a medical device company developing nitric oxide delivery systems. The company describes its recent fiscal period as a “year of meaningful transition.” It is currently undergoing a corporate update by changing its fiscal year-end from March 31st to December 31st.
On June 26, 2026, Beyond Air reported its earnings results. The company announced an earnings per share of -$0.77, which did not meet the analyst consensus estimate of -$0.57. This indicates the company’s loss per share was greater than what financial analysts had predicted for the period.
The company’s revenue for the quarter was $1.91 million, also falling short of the estimated $2.3 million. Despite this miss against estimates, Beyond Air’s full-year revenue for fiscal 2026 reached $7.7 million. This represents a significant 107% increase compared to the previous year.
The company’s financial metrics show it is not yet profitable, with a negative price-to-earnings (P/E) ratio of -0.09. A negative P/E ratio occurs when a company has negative earnings. However, its price-to-sales (P/S) ratio is 0.35, a metric often used for growth companies.
From a liquidity standpoint, Beyond Air has a current ratio of 5.12. This suggests the company has more than enough current assets to cover its short-term liabilities. Looking ahead, the company projects revenue between $16 million and $18 million for 2027.
